Conclusions Although this study shows a low prevalence of NG infection among young pregnant women in Brazil, they presented STI risk factors that justify include STI counselling for this population.

Epidemiology poster session 1: STI trends: *Neisseria gonorrhoeae*: resistance

P1-S1.38 EMERGENCE OF *NEISSERIA GONORRHOEA*E ISOLATES WITH DECREASED SUSCEPTIBILITIES TO CEFTRIAXONE AND CEFIXIME IN CANADA - 2001–2010

doi:10.1136/sextrans-2011-050108.38

¹I Martin, ¹P Sawatzky, ²V Allen, ³L Hoang, ⁴B Lefebvre, ⁵N Mina, ¹M Gilmour. ¹Public Health Agency of Canada, Winnipeg, Canada; ²Ontario Agency for Health Protection and Promotion, Public Health Laboratory, Toronto, Canada; ³British Columbia Centres for Disease Control Public Health Microbiology & Reference Laboratory, Vancouver, Canada; ⁴Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, Canada; ⁵Department of Medical Microbiology, University of Alberta, Edmonton, Canada

Background In Canada, the susceptibilities for ceftriaxone and cefixime in *Neisseria gonorrhoeae* are gradually decreasing and there has been a shift in the modal minimum inhibitory concentrations (MICs) from 0.016 µg/ml in 2000 to 0.032 µg/ml in 2008. We examined the phenotypic and genetic characteristics of *N gonorrhoeae* with decreased susceptibilities to 3rd generation cephalosporins isolated in Canada between 2001 and 2010.

Methods *N gonorrhoeae* isolates were collected by Canadian provincial public health laboratories. MICs were determined by agar dilution at the National Microbiology Laboratory (NML) and isolates displaying decreased susceptibilities to cefixime (MIC=0.25 mg/l and 0.5 mg/l) and ceftriaxone (MIC=0.125 mg/l and 0.25 mg/l) were examined using multi-antigen sequence typing (NG-MAST) and sequencing of resistance determinants associated with decreased cephalosporin susceptibilities (penA, mtrR, ponA, porB).

Results A total of 155 *N gonorrhoeae* isolates with decreased susceptibility MICs to ceftriaxone and cefixime were identified from the following provinces - Ontario (53.5%, N=83); British Columbia (34.2%, N=53); Québec (12.3%, N=19). Of the 155 isolates observed with reduced susceptibility, 23 were observed between 2001 and 2007 (14.8%), whereas in 2008, 2009 and 2010 there were 84 isolates (54.2%), 23 isolates (14.8%) and 25 isolates (16.1%) observed, respectively. Thirty-eight different NG-MAST sequence types were identified among the isolates; ST-3158, ST-225 and ST-1407 were the most prevalent at 25.9%, 19.4% and 14.8%, respectively. The mtrR resistance determinants were present in 95.5% of the isolates. The penA mosaic was present in 60% of the isolates, with the most common penA mosaic types XXXII and X identified at 51.0% and 7.7%, respectively, while the non-mosaic penA type XII was identified in 36.8% of the isolates. The G101K alteration in porB was present in 97.4% of the isolates and the A102N and A102D alterations in porB were found in 49.7% and 45.8% of the isolates, respectively. L421P alterations in ponA were present in all the isolates.

Conclusions In Canada, *N gonorrhoeae* isolates with decreased susceptibilities to 3rd generation cephalosporins, including cefixime and ceftriaxone have increased over the years. The alterations in penA, mtrR and porB are important determinants identified in these isolates. The most common ST types identified among these Canadian isolates have also been reported worldwide.

P1-S1.39 AZITHROMYCIN SUSCEPTIBILITIES IN CANADIAN *NEISSERIA GONORRHOEA*E ISOLATES (2006–2010)

doi:10.1136/sextrans-2011-050108.39

¹P Sawatzky, ¹I Martin, ²V Allen, ³L Hoang, ⁴B Lefebvre, ⁵M Lovgren, ¹M Gilmour. ¹Public Health Agency of Canada, Winnipeg, Canada; ²Ontario Agency for Health

Protection and Promotion, Public Health Laboratory, Toronto, Canada; ³British Columbia Centres for Disease Control, Public Health Microbiology & Reference Laboratory, Vancouver, Canada; ⁴Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, Canada; ⁵Alberta Health Services, Edmonton, Canada

Background Canada conducts surveillance of antimicrobial susceptibilities in *Neisseria gonorrhoeae* strains to support development of treatment guidelines.

Methods *N gonorrhoeae* strains were isolated or collected by Canadian provincial public health and reference laboratories. Minimum inhibitory concentrations (MICs) were determined by agar dilution for penicillin, spectinomycin, tetracycline, erythromycin (ery), ceftriaxone, ciprofloxacin (cip), cefixime, and azithromycin (az) at the provincial laboratories or the National Microbiology Laboratory (NML). Sequence types (ST), auxotypes, and plasmid profiles were also determined at the NML.

Results Thirty-nine strains from British Columbia (n=18), Alberta (n=2), Ontario (n=9) and Quebec (n=10) were found to be az resistant (R) (MIC≥2 µg/ml) by either a provincial laboratory or NML between 2006 and 2010. Ten different resistance profiles were represented by the 39 strains. Twenty or 51.3% were Chromosomally-Mediated Resistant *N gonorrhoeae*/azR/cipR (CMRNG/azR/cipR), 4 (10.3%) were Probable CMRNG/azR/cipR and 3 (7.7%) were Penicillinase-Producing *N gonorrhoeae*/Tetracycline-Resistant *N gonorrhoeae*/azR/cipR/eryR (PPNG/TRNG/azR/cipR/eryR). One strain was CMRNG/azR/cipR with reduced susceptibility to cefixime. Twenty-one different sequence types were determined, the most common being ST-1407 with 20.5% (8/39), ST-225 and ST-4815 with 10.3% (4/39) each. Although the estimated rate of azithromycin resistance between 2006 and 2009 is very low at 0.2% of all isolates tested across Canada (31/15487), the MICs for azithromycin are gradually increasing. In 2001, the majority of strains (27.8%) had an azithromycin MIC=0.25 µg/ml which increased to 51.5% by 2006. In 2007, the majority of strains (55.9%) had azithromycin MIC=0.5 µg/ml. The highest azithromycin MIC found was ≥64 µg/ml (n=2).

Conclusions A shift in azithromycin MICs has definitely occurred and may continue to increase. Although azithromycin is not recommended as the primary treatment for gonorrhoea, it is listed as an alternative treatment. With the increasing reduced susceptibility of our primary treatments for gonorrhoea (cefixime and ceftriaxone), azithromycin may be required to treat gonorrhoea either on its own or in combination with third generation cephalosporins. Therefore, it is imperative that azithromycin susceptibilities in *N gonorrhoeae* continue to be monitored.

P1-S1.40 EMERGING MOLECULAR MUTATIONS OF REDUCED SUSCEPTIBILITY TO THIRD-GENERATION CEPHALOSPORINS IN *NEISSERIA GONORRHOEA*E ISOLATES FROM SASKATCHEWAN, CANADA

doi:10.1136/sextrans-2011-050108.40

¹S D Thakur, ²E Nagle, ²P N Levett, ²G B Horsman, ¹Mingmin Liao, ¹J R Dillon. ¹Vaccine and Infectious Disease Organization, Saskatoon, Canada; ²Saskatchewan Disease Control Laboratory, Regina, SK, Canada

Background Third-generation cephalosporins (eg, ceftriaxone, Cro) are the antimicrobials of choice for the treatment of gonorrhoea. The molecular mechanisms causing reduced susceptibility to these antibiotics in *Neisseria gonorrhoeae* (Ng) isolates differ between isolates from different geographic regions. The objective of this research was to characterise mutations in penA, mtrR, porB and ponA associated with Cro reduced susceptibility (CroRed) in Ng isolates from Saskatchewan (SK), Canada.

Methods A total of 320 of Ng isolates (2003 to 2008) from SK were tested for their antimicrobial susceptibility to Cro using the CLSI agar dilution method. 7% of the isolates (n=23) had Cro MICs of 0.03–0.06 mg/l and were defined as having CroRed phenotypes and

93% of the isolates (n=297) had MICs of <0.03 mg/l which were classified as susceptible (CroS). All CroRed isolates were analysed for mutations in penA (PBP2), mtrR (MtrR), porB (PorB) and ponA (PBP1). 123 (42%) CroS isolates were randomly selected as coselected. **Results** In total, nine mutation patterns were observed in penA. Patterns I (31.7%), IX (29.2%) and XXII (26%) were most common in the 123 CroS isolates; while patterns IX (60.8%, $p<0.05$) and XXII (21.5%, $p>0.05$) were predominant in the 23 CroRed isolates. The mosaic penA pattern X was observed in only one isolate (Cro MIC=0.06 mg/l). Seven mutation patterns were noted in mtrR. Among the CroS isolates, 35.8% had a single mutation (G45D or A39T) in the DNA binding domain (DBD) and 17.8% of the isolates carried an Aⁿ nucleotide deletion (A⁻) in the mtr promoter coupled with a G45D mutation. Among the CroRed isolates, 65.2% carried G45D or A39T single mutations, significantly higher than that of CroS isolates ($p<0.05$). The mutation of A⁻/H105Y was observed in 21.7% of CroRed isolates as compared to 4% of CroS isolates ($p<0.05$). Five mutation patterns at residues G120 and A121 of PorB were observed in the CroRed isolates including double (47.8% vs 13% CroS isolates, $p<0.05$) or single (21.7% vs 26% CroS isolates, $p>0.05$) mutations. L421P in PBP1 was detected in 87% CroRed and 13% CroS isolates, respectively ($p<0.05$).

Conclusions Mosaic penA pattern X was only observed in one CroRed isolate. The mutations associated with CroRed phenotypes include pattern IX of PBP2, mutations in DBD and a double mutation of A⁻/H105Y in mtrR, double mutations in PorB (positions G120 and A121) and L421P of PBP1.

P1-S1.41 EMERGENCE OF AN AFRICAN ANTIMICROBIAL RESISTANCE GENOTYPE IN *NEISSERIA GONORRHOEA* STRAINS ISOLATED IN GUANGZHOU, CHINA, 2001–2009

doi:10.1136/sextrans-2011-050108.41

H P Zheng, B Yang, X Z Wu, J M Huang, W Y Zeng, Y H Xue, H N Jiang, J L Ou. Guangdong Provincial Center for Skin Diseases and STIs Control, Guangzhou, China

Background The continuing spread of drug-resistant gonococci has posed a challenge for successful treatment worldwide. Recently third-generation cephalosporins-resistant strains were isolated in Japan. Guangdong Province in South China has one of the highest gonococcal resistance rates in China and a large number of international migrants. We investigated the invitro antimicrobial susceptibility and genotypes of *N gonorrhoeae* strains isolated in Guangzhou, the capital city, from 2001 to 2009.

Methods MICs to penicillin, ceftriaxone, tetracycline, ciprofloxacin, and spectinomycin were determined by agar plate dilution and susceptibilities were interpreted according to WHO standards. β -lactamase production was determined by paper acidimetric testing. The resistant plasmids were determined for penicillinase-producing *N gonorrhoeae* (PPNG) and high-level tetracycline resistant *N gonorrhoeae* (TRNG) by PCR and the isolates were genotyped.

Results Of 1132 consecutive gonococci isolated from 2001 to 2009, no ceftriaxone and spectinomycin resistant strains were found, but the prevalence of strains less susceptible to ceftriaxone rose from 18.2% to 38.5%. The MIC₉₀ for ceftriaxone showed intermediate sensitivity (0.06–0.125 μ g/ml) and spectinomycin near the resistant level (16–32 μ g/ml). The resistance to penicillin, tetracycline and ciprofloxacin increased from 81.8%, 84.5% and 72.5% in 2001 to 90.1%, 91.4% and 98.7% in 2009, respectively. A total of 313 (27.7%) PPNG and 486 (42.9%) TRNG strains were detected. 206 (18.2%) strains were both PPNG and TRNG. PPNG rose from 21.8% to 29.8% and TRNG rapidly increased from 27.2% to 56.3%. Genotyping TEM-1 gene showed 267 (99.6%) PPNGs in 2001–2008 carried the Asian-type β -lactamase plasmids and one African-type in 2008. Genotyping of tetM gene showed that all 486 TRNGs were Dutch variants.

Conclusion Gonorrhoea resistance continues to be a major public health problem in Guangzhou. The emergence of an African gonor-

rhoea resistance variant may be related to the large African diaspora in Guangzhou, migration of Chinese to Africa, or other migration patterns. More research is needed to determine what practices, systems, and behaviours contribute to escalating resistance patterns.

Abstract P1-S1.41 Figure 1 Resistance of *N gonorrhoeae* isolates in Guangzhou during 2001–2009.

P1-S1.42 RUSSIAN GONOCOCCAL ANTIMICROBIAL SUSCEPTIBILITY PROGRAMME (RU-GASP) - RESISTANCE LEVELS IN 2010 AND TRENDS DURING 2005–2010

doi:10.1136/sextrans-2011-050108.42

¹N Frigo, ²M Unemo, ¹A Kubanova, ¹A Kubanov, ¹V Solomka, ¹S Polevshikova, ³I Lesnaya. ¹State Research Centre for Dermatology and Venereology Russian Ministry Health, Russian Federation; ²Swedish Reference Laboratory for Pathogenic Neisseria, Örebro, Sweden; ³Polevshikova, Russian Federation

Background Antimicrobial resistance (AMR) in *Neisseria gonorrhoeae* is a major concern worldwide. AMR surveillance globally is crucial for guiding effective treatment and accordingly for public health purposes. In the former Soviet countries, the knowledge regarding AMR has been limited. However, in 2004 the Russian gonococcal antimicrobial susceptibility programme (RU-GASP), which now acts also under WHO protocols, was initiated. The aims of the present study were to examine and describe the prevalence of *N gonorrhoeae* AMR in 2010 in Russia, and reveal trends during 2005–2010.

Methods In 2010, *N gonorrhoeae* isolates (one isolate per patient; n=407) collected from 46 surveillance sites distributed in all eight Federal Districts of Russia were examined regarding their susceptibility to ceftriaxone, spectinomycin, azithromycin, penicillin G, ciprofloxacin, and tetracycline using agar dilution method, according to CLSI and WHO protocols. β -Lactamase production was identified using nitrocefin discs.

Results In 2010, the AMR (intermediate susceptibility) levels were as follows - ceftriaxone 0% (0%), spectinomycin 4.4% (12.3%), azithromycin 4.9% (10.4%), penicillin G 32.5% (39.9%), ciprofloxacin 53.2% (3.0%), and tetracycline 41.9% (26.6%). Three isolates (0.7%) were resistant to all antimicrobials except ceftriaxone. During 2005–2010, the AMR has remained high to penicillin G, tetracycline, and ciprofloxacin. The proportion of resistant isolates to spectinomycin and azithromycin has ranged from 0% (2005) to 7.2% (2008), and 0.4% (2008) to 4.9% (2010), respectively. All isolates in 2005–2010 were susceptible to ceftriaxone. Nevertheless, the minimum inhibitory concentration (MIC) distribution of ceftriaxone has rapidly shifted to higher MICs, and isolates at the breakpoint for intermediate susceptibility/resistance (0.25 mg/l; n=8 [2%] in 2010) have rapidly increased over the years.

Conclusions The AMR of *N gonorrhoeae* in Russia is high and ceftriaxone (3250 mg) should be first-line for empirical treatment. If there are no access to ceftriaxone or in the presence of severe β -lactam antimicrobial allergy, spectinomycin is recommended for use.